Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone.
about
Risperidone versus other atypical antipsychotics for schizophreniaOlanzapine versus other atypical antipsychotics for schizophreniaAntipsychotic medication for early episode schizophreniaMetabolic Issues With Atypical Antipsychotics in Primary Care: Dispelling the MythsManagement of antipsychotic-related weight gainAcute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophreniaCurrent Data on and Clinical Insights into the Treatment of First Episode Nonaffective Psychosis: A Comprehensive ReviewMetabolic risk factor profile associated with use of second generation antipsychotics: a cross sectional study in a Community Mental Health CentreExcessive weight gain after remission of depression in a schizophrenic patient treated with risperidone: case report.Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis.Antipsychotic treatments for the elderly: efficacy and safety of aripiprazole.Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia.Does participation in a weight control program also improve clinical and functional outcomes for Chinese patients with schizophrenia treated with olanzapine?Reduced accumbens dopamine in Sprague-Dawley rats prone to overeating a fat-rich diet.Risk factors for obesity in adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study.Prevalence of cardiovascular risk factors among racial and ethnic minorities with schizophrenia spectrum and bipolar disorders: a critical literature review.Almost all antipsychotics result in weight gain: a meta-analysis.Eating and weight related cognitions in people with Schizophrenia : a case control studyMood Disorders in Family Practice: Beyond Unipolarity to BipolarityGenetic and Clinical Factors Affecting Plasma Clozapine ConcentrationNeural changes associated with appetite information processing in schizophrenic patients after 16 weeks of olanzapine treatment.Relationships between Brain Structure and Metabolic Changes in Schizophrenia Patients Treated with Olanzapine: A Voxel-Based Morphometric Study.Correlates of weight gain during long-term risperidone treatment in children and adolescentsA Longitudinal Study of Relation between Side-effects and Clinical Improvement in Schizophrenia: Is There a Neuro-metabolic Threshold for Second Generation Antipsychotics?Antipsychotic-induced metabolic and cardiovascular side effects in schizophrenia: a novel mechanistic hypothesis.Early evaluation of patient risk for substantial weight gain during olanzapine treatment for schizophrenia, schizophreniform, or schizoaffective disorderEthnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophrenia.The association between weight change and symptom reduction in the CATIE schizophrenia trial.Pharmacogenetics of leptin in antipsychotic-associated weight gain and obesity-related complicationsTime-dependent effects of haloperidol on glutamine and GABA homeostasis and astrocyte activity in the rat brain.Associations among obesity, acute weight gain, and response to treatment with olanzapine in adolescent schizophrenia.Contours of usual care: meeting the medical needs of diverse people with serious mental illness.Effect of chronic infusion of olanzapine and clozapine on food intake and body weight gain in male and female rats.Dose-dependent acute excessive weight gain and metabolic changes in a drug-naive patient on risperidone are reversible with discontinuation: a case report.The Complex Relationship between Antipsychotic-Induced Weight Gain and Therapeutic Benefits: A Systematic Review and Implications for Treatment.
P2860
Q24234950-337E2C4C-62A8-4449-8B85-0899C87BA45BQ24236545-30AB115F-D464-4DA8-8FA2-873717617C01Q24236683-623867BF-94BC-413A-AD04-6D2192C2B224Q24596954-E1FCA559-A645-4465-BDD3-D004CB129CE9Q24610124-354F0CF6-E3BC-4CC7-AD29-E4E20012D341Q24798487-A758A1D6-009E-47CA-8DC4-628906FE54FDQ28079821-DEBA2C30-9FC5-4C49-A979-FE86F023FAA4Q33236751-5C934182-A1BF-431C-9F18-38724DD11E0FQ33256430-2165D330-EA18-43FE-AF53-9C486894B063Q33423275-DC65FD87-B95E-4382-AC4D-7DBE047D06E7Q33755676-E191D453-9200-4829-9F79-FD9721B693D0Q33821379-2202DFBF-4A8E-4179-9DBB-9277804DC322Q33895407-FE19AD3D-27E6-4EBB-AF79-BD9273F482A7Q34095392-6A231620-077D-4906-A0E5-2C2C9EDC6FD4Q34106516-86BBEEDE-9B66-45D7-A83A-CE2B5BDF9831Q34181934-E8A10BD4-D202-4D0A-9BCB-41D9BB18F065Q34661499-4794CDE7-63E7-4C4A-93EE-082F0B2F3DECQ35126654-70514F49-D931-4F4D-A67B-A543773653B9Q35160527-3E8A6232-1986-4758-9737-92916884A9ECQ35746655-C8489740-AD34-462C-B239-F388031053F0Q36061639-E9B119B3-70F8-492F-BBBC-DB5C8CDCFBF6Q36169521-49C5068D-302A-4BB3-9AA5-8A2C54482A0CQ36373562-15ECC061-5A0B-4EBD-9EDA-FC86C70621BAQ36832340-425F9F1B-6180-4A6D-B4F8-CE4B816A9321Q36852489-DBF1AC74-E4D1-43A4-91BB-D1C6DF484683Q36934711-A637C078-1BF6-4559-A54A-6143B7611DD0Q37162718-6DC4FB51-CC90-450F-9EE5-154C3A39F216Q37212106-8886DE33-576E-4A7B-B096-34230F17480BQ37220366-61F8FBF2-0D0A-4A9E-A9BE-A5F142EF2365Q37230904-EAB08905-9B54-499B-B825-40619520746EQ37244634-CC3DF83A-B6B2-496C-BE3C-68FEDC3F0CCBQ37453862-49CE813E-0CB1-4CF7-8CC7-E2E281C1703AQ37721501-DDB17D26-A0D9-46BA-98A2-25BB11FEB4E6Q42958189-90EB1D94-30C4-49EC-9751-2AF374DE7612Q49481418-319C7D7A-5EC3-45C9-AD2E-0AB3E00C3EF9
P2860
Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Factors influencing acute weig ...... , haloperidol, or risperidone.
@en
Factors influencing acute weig ...... , haloperidol, or risperidone.
@nl
type
label
Factors influencing acute weig ...... , haloperidol, or risperidone.
@en
Factors influencing acute weig ...... , haloperidol, or risperidone.
@nl
prefLabel
Factors influencing acute weig ...... , haloperidol, or risperidone.
@en
Factors influencing acute weig ...... , haloperidol, or risperidone.
@nl
P2093
P1476
Factors influencing acute weig ...... , haloperidol, or risperidone.
@en
P2093
B R Basson
C C Taylor
G D Tollefson
J A Gilmore
K A Szymanski
P304
P577
2001-04-01T00:00:00Z